Pregnancy, spontaneous or induced vaginal delivery and elective cesarean section Pregnancy and Childbirth
Conditions
Interventions
Current interventions as of 20/09/2019:
The aim is to recruit altogether 600 patients in the following three groups:
1. 200 late and post term gravidae (41+0 or more we
Sponsors
Helsinki University Central Hospital
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: Current participant inclusion criteria 20/09/2019: 1. Female 2. Age 18 or older Further inclusion criteria for different study arms: Post-term induction study arm: 1. Patients have more than 41+0 pregnancy weeks 2. Intact membranes before the induction of labor Early-term and full-term parturition study arm: 1. Patients come to the delivery ward with contractions and intact membranes 2. Patients have 37+0-40+6 pregnancy weeks Cesarean section study arm: 1. Patients are scheduled for an elective cesarean section 2. Patients have 37+0-40+6 pregnancy weeks on the scheduled cesarean section date Previous participant inclusion criteria: 1. Female 2. Age 18 to 45 Further inclusion criteria for different study arms: Post-term induction study arm: 1. Patients have more than 41+0 pregnancy weeks 2. Intact membranes before the induction of labor Early-term and full-term parturition study arm: 1. Patients come to the delivery ward with contractions and intact membranes 2. Patients have 37+0-40+6 pregnancy weeks Cesarean section study arm: 1. Patients are scheduled for an elective cesarean section 2. Patients have 37+0-40+6 pregnancy weeks on the scheduled cesarean section date
Exclusion criteria
Exclusion criteria: 1. Breech presentation in vaginal delivery 2. Non-singleton pregnancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Vaginal microbiome composition assessed using Illumina Miseq or HiSeq technology targeting the V3-V4 region of 16S rRNA gene All of the outcomes are measured at baseline. In the post term induction study group and early and full term study group the outcomes are also measured during the induction and parturition. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Vaginal cytokine profile measured using multiplex ELISA and/or Luminex 2. Vaginal proteomic profile measured using tandem mass spectrometry 3. Bacterial metabolites analyzed with NMR spectroscopy All of the outcomes are measured at baseline. In the post term induction study group and early and full term study group the outcomes are also measured during the induction and parturition. | — |
Countries
Finland
Contacts
Public ContactKaisa Kervinen
Outcome results
None listed